Quanterix Corporation(NasdaqGM: QTRX) dropped from Russell 3000E Growth Benchmark
Quanterix Corporation (NasdaqGM: QTRX) has been removed from the Russell 3000E Growth Benchmark. The article also provides recent news about the company, including management changes, quarterly earnings results, and presentations at financial conferences. It also includes financial data, analyst consensus, and a company profile for Quanterix Corporation.
Quanterix Corporation(NasdaqGM:QTRX) dropped from Russell Small Cap Comp Growth Benchmark
Quanterix Corporation (NasdaqGM:QTRX) has been removed from the Russell Small Cap Comp Growth Benchmark, as announced on June 29, 2026. This news comes alongside several recent updates for the company, including presentations at a Goldman Sachs conference and changes to its executive leadership, including the appointment of a new CFO, Jason Faessler. Quanterix specializes in ultra-sensitive biomarker detection technology for disease research, diagnostics, and drug development.
Quanterix Corporation Actuals & Estimates (NASDAQ:QTRX)
This article provides an overview of Quanterix Corporation (NASDAQ: QTRX) stock performance, financial actuals, and analyst estimates. It includes current stock price, recent performance trends, market capitalization, earnings estimates, revenue figures, and employee count. The article also touches on volatility, analyst forecasts, and historical high/low prices for QTRX.
Enterprise value to EBITDA forward of Quanterix Corporation – NASDAQ:QTRX
This article displays the "Enterprise value to EBITDA forward" metric for Quanterix Corporation (NASDAQ: QTRX) on TradingView. It provides financial data for the company under the Health Technology sector. The content itself is an excerpt from a financial data platform, showcasing the metric without further textual analysis.
Enterprise value to revenue forward of Quanterix Corporation – NASDAQ:QTRX
This article displays financial information for Quanterix Corporation (NASDAQ: QTRX), specifically its enterprise value to revenue forward metric. It's presented within a TradingView interface, showing market data from various providers like ICE Data Services and FactSet. The content primarily focuses on the display of this financial statistic for the company.
QTRX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Quanterix Corporation (QTRX) stock, including analyst price targets and predictions for 2027. It details recent stock performance, financial metrics like EPS and revenue, and upcoming earnings dates. The article also answers frequently asked questions about QTRX's market capitalization, volatility, and historical price movements.
QTRX - Quanterix Corp Volatility & Greeks
This article provides a detailed financial overview of Quanterix Corp (QTRX), including its stock performance, key financial metrics, and volatility data. It lists various ratios such as P/E, P/S, ROA, and highlights insider and institutional ownership, alongside short interest figures. The data presented covers the company's financials up to July 2, 2026, offering insights into its current market position and historical performance.
Quanterix Stock Is Popping In Pre-Market: Here's Why
Quanterix Corporation (NASDAQ: QTRX) stock surged 5.28% in pre-market trading after Securities and Exchange Commission filings revealed outgoing CFO Vandana Sriram vested and forfeited some restricted stock units. Jason Faessler officially assumed the CFO role, joining from Bruker Corporation. The article also provides trading metrics and technical analysis for QTRX.
Quanterix Corp (QTRX) Valuation: PE, PB & Fair Value Analysis
Quanterix Corp (QTRX) currently holds a valuation score of 7.38, placing it 163rd out of 203 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -1.83, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Quanterix Corp sets out growth plans, shares trade on Nasdaq
Quanterix Corp is gaining investor attention with its digital biomarker platform and recent operational milestones, with its shares trading on Nasdaq. The company focuses on developing ultra-sensitive digital biomarker assays based on its proprietary Simoa technology, targeting pharmaceutical and academic research as well as diagnostic partners. Quanterix generates revenue through the sale of Simoa instruments, consumable assay kits, and related services, emphasizing collaborations to expand assay menus and stabilize revenue streams.
Quanterix (QTRX) CFO adds stock as RSUs vest and shares withheld
Quanterix CFO Vandana Sriram reported that 1,833 restricted stock units (RSUs) converted into common stock on June 15, 2026. Of these, 548 shares were withheld at $3.10 per share to cover tax obligations, which is a routine part of equity compensation. Following these transactions, Sriram directly owns 30,261 shares of Quanterix common stock.
Form 4 Quanterix Corp For: 23 June
This article provides an announcement regarding a Form 4 filing for Quanterix Corp on June 23. It also includes a standard disclaimer about the risks associated with trading financial instruments and cryptocurrencies, emphasizing market volatility and the importance of informed decisions. The content reminds users that data on the Investing.com website may not always be real-time or accurate, being indicative rather than definitive.
TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today
Trinity Biotech (TRIB), Recon Technology (RCON), and Quanterix Corp. (QTRX) all experienced double-digit after-hours gains driven by different factors. Trinity's surge followed the launch of Trinovium, a subsidiary for AI data center liquid-cooling solutions, while Quanterix rose due to a completed leadership transition with a new CFO. Recon Technology's significant rebound was attributed to speculative buying and short covering after hitting a record low.
Form 4 Quanterix Corp For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Quanterix Corp on June 23. It includes general stock market performance data for various indices, commodities, bonds, and individual stocks. The content indicates it's a routine financial news update on a company's SEC filing.
Form 4 Quanterix Corp For: 23 June By Investing.com
This article from Investing.com reports on a Form 4 filing for Quanterix Corp (QTRX) on June 23rd. The brief piece indicates that QTRX saw a 14.89% increase. No further details about the filing are provided.
TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today
Trinity Biotech (TRIB), Quanterix Corp. (QTRX), and Recon Technology (RCON) each experienced significant after-hours gains. TRIB surged after announcing a new subsidiary, Trinovium, focused on liquid-cooling solutions for AI data centers. QTRX rose as its new CFO officially took office, completing a leadership overhaul, while RCON saw a technical rebound from a record low, driven by speculative buying and short covering.
Quanterix (QTRX) CFO Jason Faessler files initial Form 3 ownership
Quanterix Corp's new Chief Financial Officer, Jason F. Faessler, has filed his initial Form 3, which is required for insiders. This filing indicates his beneficial ownership but reports no transactions in Quanterix stock, nor any option exercises or other related financial activity. The document establishes his insider status without disclosing any current equity changes.
Quanterix Corp (QTRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Quanterix Corp (QTRX), highlighting its current price momentum score of 6.50 within the Healthcare Equipment & Supplies industry. It identifies key support at $2.54 and resistance at $4.13, suggesting suitability for range-bound swing trading. The analysis also details various technical indicators and moving averages, concluding with a "Buy" signal based on these metrics.
Quanterix Corp (QTRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Quanterix Corp (QTRX), categorized by business segments and geographical regions. As of April 6 (year not specified), product revenue accounts for 67.03% of the total, services for 31.89%, and collaboration/license revenue for 1.08%. Geographically, North America contributes 61.39% of revenue, EMEA 26.48%, and Asia Pacific 12.13%.
Quanterix Corp (QTRX) Institutional Confidence
Quanterix Corp (QTRX) has a strong institutional confidence score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional shareholding stands at 90.49%, showing a quarter-over-quarter increase. First Eagle Investment is the largest institutional shareholder, holding 1.73 million shares.
Quanterix Corp (QTRX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Quanterix Corp (QTRX), listing major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activity with changes in holdings for key investors. The article also lists various ETFs that hold QTRX shares.
Quanterix Corp (QTRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Quanterix Corp (QTRX), highlighting its current earnings forecast score, average price target of $6.50, and a "Hold" analyst rating based on 3 analysts. It also includes anticipated revenue for the next quarter, expected EPS, and a peer comparison within the Healthcare Equipment & Supplies industry.
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Quanterix Corporation has reported inducement grants made under Nasdaq Listing Rule 5635(C)(4). This brief announcement indicates compliance with Nasdaq regulations regarding specific types of equity-based compensation for new employees. The information is provided by Refinitiv and applies to the company under the stock symbol QTRX.
Quanterix (QTRX) CTO exercises 1,558 RSUs; 467 shares withheld for taxes
Quanterix Corp's Chief Technology Officer, Michael Francis Miller, exercised 1,558 restricted stock units (RSUs) and had 467 shares withheld for tax obligations at $3.10 per share. Following these transactions, Miller directly holds 33,851 common shares. The filing indicates routine equity compensation activity and tax withholdings, not open-market sales.
Biotech Quanterix gives new staff 336,804 stock units over 4 years
Quanterix Corporation announced inducement grants of 336,804 restricted stock units (RSUs) to three new employees on June 15, 2026. These RSUs, representing shares of Quanterix common stock, will vest in four equal annual installments, contingent on continued employment. The grants were made under the company’s Amended and Restated 2025 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4).
Quanterix CCO Benjamin Meadows buys $9,695 in company stock
Quanterix CCO Benjamin Meadows recently purchased 3,500 shares of the company's common stock for $9,695. This transaction comes as the stock has seen a significant decline. Other recent company news includes beat-expectations Q1 2026 earnings per share, a revenue shortfall, and new appointments to its leadership team, including a new CFO and SVP of Diagnostics focusing on Alzheimer's Disease.
Quanterix CCO Benjamin Meadows buys $9,695 in company stock By Investing.com
Quanterix CCO Benjamin Meadows recently purchased 3,500 shares of company stock for $9,695, indicating a potential undervalued stock according to InvestingPro analysis despite a 60% decline in the past six months. This transaction follows the company's Q1 2026 earnings report, which exceeded EPS expectations but missed revenue targets, and recent leadership changes including a new CFO and a Senior VP for Diagnostics. These developments aim to strengthen Quanterix's leadership and strategic focus.
Quanterix (QTRX) Chief Commercial Officer buys 3,500 shares in open-market trade
Quanterix's Chief Commercial Officer, Benjamin Meadows, recently purchased 3,500 shares of company common stock in an open-market transaction. The shares were bought at a price of $2.77 per share on May 12, 2026, increasing his direct holdings to 3,500 shares. This transaction, detailed in a Form 4 SEC filing, indicates an insider purchase valued at $9,695.
Quanterix (QTRX) CCO Benjamin Meadows reports options, RSUs and PSUs in Form 3
Quanterix CCO Benjamin Meadows has filed a Form 3, disclosing his initial equity holdings in the company. These holdings include 76,234 stock options with an exercise price of $5.88, 22,959 restricted stock units granted on October 6, 2025, and an additional 70,223 restricted stock units and 70,223 performance stock units granted on February 15, 2026. This filing outlines the vesting schedules for these equity awards, linking them to continued service and performance conditions.
Quanterix Appoints Jason Faessler as New Chief Financial Officer
Quanterix (QTRX) has named Jason Faessler as its new Chief Financial Officer and Treasurer, effective June 22, 2026, to strengthen its financial leadership for strategic growth initiatives. Faessler brings extensive experience from previous finance roles and will be crucial in capital planning and operational finance. His compensation package includes a significant annual salary, a sign-on bonus, performance bonuses, and long-term equity, reflecting the company's commitment to securing experienced financial guidance.
Transcript : Quanterix Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01
This article provides a transcript of Quanterix Corporation's presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The content includes an introduction by an analyst and the beginning of a presenter's speech, indicating that the full transcript is available to subscribers. Also included are recent news updates about Quanterix, such as executive appointments and financial results.
Quanterix Appoints Jason Faessler as Chief Financial Officer
Quanterix Corporation (Nasdaq: QTRX) has appointed Jason Faessler as its new Chief Financial Officer, effective June 22. Faessler brings extensive financial leadership experience from the life sciences and healthcare sectors, including roles at Bruker Corporation and PAREXEL. His appointment is expected to strengthen Quanterix's executive leadership as the company advances its growth strategy in research, diagnostics, and precision medicine, particularly following its acquisition of Akoya Biosciences to expand spatial biology capabilities.
Quanterix Appoints Jason Faessler as New CFO to Drive Strategic Growth in Life Sciences Industry
Quanterix Corporation has appointed Jason Faessler as its new Chief Financial Officer, effective June 22, 2026, to bolster strategic growth in the life sciences industry. Faessler brings extensive experience from previous senior finance roles, including at Bruker Corporation and PAREXEL, to Quanterix's growth plans. This leadership change, alongside the recent acquisition of Akoya Biosciences, is expected to enhance Quanterix's market position in precision medicine and potentially impact its share price.
Quanterix appoints Jason Faessler as CFO and Treasurer
Quanterix (QTRX) has announced the appointment of Jason Faessler as its new Chief Financial Officer and Treasurer, effective June 22, 2026. Faessler previously served as SVP of Finance at Brucker Corporation and held prior roles at Parexel, Harvard Business Publishing, and EMC. He holds an MBA from Babson College and a BA from UMass Boston.
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
Quanterix Corporation has appointed Jason Faessler as its new Chief Financial Officer, effective June 22, 2026. Faessler brings extensive experience from the life science tools industry, previously serving as Senior Vice President at Bruker Corporation. He is expected to play a key role in advancing Quanterix's strategic growth plans and mission by contributing his expertise in financial planning and operational excellence.
Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer
Quanterix Corporation has announced the appointment of Jason Faessler as its new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience from the life science tools industry, previously serving as Senior Vice President leading global FP&A and Americas Finance at Bruker Corporation. He is expected to play a crucial role in advancing Quanterix's strategic growth plans and mission of enabling earlier disease detection and deeper insights in both research and clinical settings.
From Bruker to Quanterix: Jason Faessler takes over as CFO
Quanterix Corporation has announced the appointment of Jason Faessler as its new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience from Bruker Corporation and PAREXEL, which will be instrumental in executing Quanterix's strategic growth plans. The company aims to advance its mission of accelerating biomarker breakthroughs from discovery to diagnostics.
Jason Faessler joins Quanterix (QTRX) as Chief Financial Officer and Treasurer
Quanterix Corporation has appointed Jason Faessler as its new Chief Financial Officer and Treasurer, with his employment commencing on June 22, 2026. Faessler brings extensive finance leadership experience from various companies, including Bruker Corporation and PAREXEL. His compensation package includes an annual base salary of $475,000, a $200,000 cash sign-on bonus, and eligibility for an annual performance bonus, along with restricted stock units.
Quanterix Appoints Industry Veteran Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
Quanterix has announced the appointment of Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. This strategic hiring aims to leverage Albrecht's industry experience to further develop the company's diagnostics sector. Quantisnow, a real-time market data platform, alerted its members to this development shortly after its publication.
Quanterix Corporation Appoints Geoff Albrecht as Senior Vice President and General Manager of Diagnostics
Quanterix Corporation has appointed Geoff Albrecht as Senior Vice President and General Manager of Diagnostics. Albrecht, with over 25 years of commercial leadership experience from Quest Diagnostics, will lead the company's Diagnostics strategy, starting with Alzheimer's Disease, and aim to scale the portfolio into a significant revenue driver. He will report directly to the CEO, emphasizing Quanterix's commitment to growing its diagnostics business.
Quanterix Appoints Geoff Albrecht to Lead Diagnostics Business Expansion
Quanterix Corporation (Nasdaq: QTRX) has appointed Geoff Albrecht as Senior Vice President and General Manager of Diagnostics to accelerate the commercialization of its diagnostics portfolio, particularly in Alzheimer's disease testing. Albrecht, formerly of Quest Diagnostics, will report to CEO Everett Cunningham and focus on scaling Quanterix's diagnostics business into a significant revenue driver. This appointment aligns with Quanterix's strategy to expand beyond biomarker research tools and strengthen its presence in clinical diagnostics.
Quanterix appoints Geoff Albrecht to lead diagnostics unit By Investing.com
Quanterix Corporation has appointed Geoff Albrecht as Senior Vice President and General Manager of Diagnostics to lead the company's diagnostics strategy, particularly in Alzheimer’s Disease. Albrecht, with extensive commercial leadership experience from Quest Diagnostics, will report to CEO Everett Cunningham and join the Executive Leadership Team. This move is part of Quanterix's growth strategy to expand its diagnostics business, supported by financial stability and recent stock rebound, despite a reported revenue miss in Q1 2026 and the upcoming departure of its CFO.
Former Quest exec Geoff Albrecht to lead Quanterix Alzheimer’s diagnostics
Quanterix has appointed Geoff Albrecht as Senior Vice President and General Manager of Diagnostics, signaling a major push to expand its diagnostics business, starting with Alzheimer's Disease. Albrecht, who brings over 25 years of commercial leadership experience from Quest Diagnostics, will lead the company's diagnostics strategy and the development of the necessary infrastructure to scale this portfolio. This strategic hire underscores Quanterix's commitment to making diagnostics a fundamental pillar of its future growth and commercial strategy.
Quanterix to Take Part in Conference
Quanterix Corporation announced its senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. CEO Everett Cunningham will give a fireside chat on June 9, providing updates on the company and its strategic priorities. Quanterix, a leader in ultra-sensitive biomarker detection, recently acquired Akoya Biosciences to integrate biology across blood and tissue for precision medicine.
Quanterix CEO to host June 9 fireside chat at Goldman Sachs healthcare event
Quanterix Corporation (Nasdaq: QTRX) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026, in Miami, FL. CEO Everett Cunningham will host a fireside chat on June 9 at 1:20 pm ET to discuss company updates and strategic priorities, and the company will also hold one-on-one investor meetings. A live webcast of the presentation will be available on the company's investor relations website, with a replay accessible afterwards.
EDGAR Filing Documents for 0001503274-26-000011
This EDGAR filing details a Form 8-K current report (Accession No. 0001503274-26-000011) filed by Quanterix Corp (CIK: 0001503274) on March 2, 2026. The report includes results of operations and financial condition, along with various exhibits such as financial statements, earnings presentations, and XBRL data files.
QTRX Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Quanterix Corp (QTRX), indicating a "Sell" consensus based on various indicators. It details moving averages, momentum oscillators like RSI and MACD, and identifies key support and resistance levels. The report highlights that QTRX is trading below its 60-day and 200-day moving averages, reinforcing the bearish outlook.
Quanterix Corporation - Common Stock (NQ: QTRX)
This article provides recent news headlines related to Quanterix Corporation (NASDAQ: QTRX), including the FDA expanding its COVID-19 antigen test EUA label, a look into its Q2 sales and earnings, and its Relative Strength Rating improvements. It also covers related news about Cassava Sciences and other market movers.
CCORF Maintains Quanterix(QTRX.US) With Hold Rating, Maintains Target Price $4
CCORF has reiterated its Hold rating for Quanterix (QTRX.US) and maintained its target price at $4. This indicates that the firm's outlook on Quanterix has not changed, suggesting they do not foresee significant upward or downward movement for the stock in the near term based on current information.
Quanterix Reshapes Leadership, Appoints Anthony Catalano COO
Quanterix (QTRX) has appointed Anthony Catalano as Chief Operating Officer, formalizing his role with an employment agreement including a $400,000 base salary, a $50,000 sign-on bonus, and equity. Former COO Michael Miller transitions to Chief Technology and Products Officer. This leadership restructuring aims to support operational execution and product strategy for the company, which specializes in ultra-sensitive biomarker detection technologies.
